摘要
目的观察并初步探讨二肽基肽酶4(Dipeptidyl peptidase 4,DPP4)抑制剂西格列汀联合二甲双胍治疗2型糖尿病的临床疗效。方法选择2014年1月至2015年2月来我院就诊的63例2型糖尿病患者作为研究对象,随机分为3组。对照组单一给药二甲双胍(A组)、西格列汀(Sitagliptin)(B组),观察组(C组)给予西格列汀联合二甲双胍治疗,治疗12周后检测并观察各组总体疗效及相关生化指标。结果 C组治疗后空腹血糖(FBG)、餐后2小时血糖(2h BG)分别为(7.4±1.7)、(8.2±1.9)mmol/L,与A组、B组相比显著降低,差异有统计学意义(P<0.05)。C组糖化血红蛋白(Hb A1c)、体重指数(BMI)及血尿酸(UA)均较A组、B组呈下降趋势,但差异无统计学意义(P>0.05)。结论 DPP4抑制剂西格列汀联合二甲双胍治疗2型糖尿病疗效显著,能够全面控制血糖,降低体重,降低血尿酸,不增加低血糖的发生,具有良好的安全耐受性,值得临床应用推广。
Objective To investigate the effects of dipeptidyl peptidase 4 inhibitor （ sitag liptin） combined with metformin in the treatment of patients with type 2 diabetes mellitus. Methods Totally 63 cases of type 2 diabetes in our hospital from January 2014 to February 2015 were selected and randomly divided into three groups： control group （group A,group B） was given single use of metformin （group A） or sitagliptin （group B） ;observation group （group C） was given metformin combined with sitagliptin. Biochemical indicator was determined, and overall curative effect was observed after 12 weeks of treatment. Resnlts The fasting blood glucose and 2-hour postprandial blood glucose of group C was （7.4 ± 1.7） and （8.2 ± 1.9） mmol/L respectively,which was lower than that of group A and group B （P〈0.05）.The levels of glycated hemoglobin blood （HbAlc）,body mass index （BMI） and uric acid （UA） of group C were slightly lower than those of group A and group B, but there was no significant difference （ P 〉 0. 05 ）. Conclusion Sitagliptin combined with metformin has significant curative effect in the treatment of type 2 diabetes mellitus, which can control diabetes generally, reduce body weight and decrease the serum UA levels with a good safety and tolerance. It is worth using in clinical practice.
出处
《实用药物与临床》
CAS
2016年第9期1094-1097,共4页
Practical Pharmacy and Clinical Remedies
